Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan


      The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak poses a major challenge in the treatment decision-making of patients with cancer, who may be at higher risk of developing a severe and deadly SARS-CoV-2 infection compared with the general population. The health care emergency is forcing the reshaping of the daily assessment between risks and benefits expected from the administration of immune-suppressive and potentially toxic treatments.
      To guide our clinical decisions at the National Cancer Institute of Milan (Lombardy region, the epicenter of the outbreak in Italy), we formulated Coronavirus-adapted institutional recommendations for the systemic treatment of patients with gastrointestinal cancers. Here, we describe how our daily clinical practice has changed due to the pandemic outbreak, with the aim of providing useful suggestions for physicians that are facing the same challenges worldwide.


      To read this article in full you will need to make a payment


      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Ministero della Salute. Novel coronaviris.
        (Available at:)
        • Yu J.
        • Ouyang W.
        • Chua M.L.K.
        • Xie C.
        SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China.JAMA Oncol 2020 Mar 25;e200980.
        (Online ahead of print)
        • Liang W.
        • Guan W.
        • Chen R.
        • et al.
        Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.
        Lancet Oncol. 2020; 21: 335-337
        • Wang D.
        • Hu B.
        • Hu C.
        • et al.
        Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.
        JAMA. 2020; 323: 1061-1069
        • National Institute for Health Care and Excellence
        Coronavirus (COVID-19).
        (Available at:)
        Date accessed: April 3, 2020
        • Hanna T.P.
        • Evans G.A.
        • Booth C.M.
        Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic.
        Nat Rev Clin Oncol. 2020; 17: 268-270
        • Pietrantonio F.
        • Miceli R.
        • Raimondi A.
        • et al.
        Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer.
        J Clin Oncol. 2019; 37: 3392-3400
        • Al-Batran S.E.
        • Homann N.
        • Pauligk C.
        • et al.
        • FLOT4-AIO Investigators
        Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
        Lancet. 2019; 393: 1948-1957
        • Kattan M.W.
        • Karpeh M.S.
        • Mazumdar M.
        • Brennan M.F.
        Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma.
        J Clin Oncol. 2003; 21: 3647-3650
        • Noh S.H.
        • Park S.R.
        • Yang H.K.
        • et al.
        • CLASSIC trial investigators
        Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
        Lancet Oncol. 2014; 15: 1389-1396
        • Cunningham D.
        • Starling N.
        • Rao S.
        • et al.
        • Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom
        Capecitabine and oxaliplatin for advanced esophagogastric cancer.
        N Engl J Med. 2008; 358: 36-46
        • Al-Batran S.E.
        • Hartmann J.T.
        • Probst S.
        • et al.
        • Arbeitsgemeinschaft Internistische Onkologie
        Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
        J Clin Oncol. 2008; 26: 1435-1442
        • Wagner A.D.
        • Syn N.L.
        • Moehler M.
        • et al.
        Chemotherapy for advanced gastric cancer.
        Cochrane Database Syst Rev. 2017; 8: CD004064
        • Bang Y.J.
        • Van Cutsem E.
        • Feyereislova A.
        • et al.
        • ToGA Trial Investigators
        Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
        Lancet. 2010; 376: 687-697
        • Rivera F.
        • Romero C.
        • Jimenez-Fonseca P.
        • et al.
        Phase II study to evaluate the efficacy of trastuzumab in combination with capecitabine and oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
        Cancer Chemother Pharmacol. 2019; 83: 1175-1181
        • Ryu M.H.
        • Yoo C.
        • Kim J.G.
        • et al.
        Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer.
        Eur J Cancer. 2015; 51: 482-488
        • Ford H.E.
        • Marshall A.
        • Bridgewater J.A.
        • et al.
        • COUGAR-02 Investigators
        Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.
        Lancet Oncol. 2014; 15: 78-86
        • Fuchs C.S.
        • Moore M.R.
        • Harker G.
        • Villa L.
        • Rinaldi D.
        • Hecht J.R.
        Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.
        J Clin Oncol. 2003; 21: 807-814
        • Thuss-Patience P.C.
        • Kretzschmar A.
        • Bichev D.
        • et al.
        Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
        Eur J Cancer. 2011; 47: 2306-2314
        • Pietrantonio F.
        • Barretta F.
        • Fanotto V.
        • et al.
        Estimating survival probabilities of advanced gastric cancer patients in the second-line setting: the gastric life nomogram.
        Oncology. 2018; 95: 344-352
        • Catalano V.
        • Graziano F.
        • Santini D.
        • et al.
        Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?.
        Br J Cancer. 2008; 99: 1402-1407
        • Wilke H.
        • Muro K.
        • Van Cutsem E.
        • et al.
        • RAINBOW Study Group
        Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
        Lancet Oncol. 2014; 15: 1224-1235
        • Rogers J.E.
        • Xiao L.
        • Amlashi F.G.
        • et al.
        Ramucirumab and paclitaxel administered every 2 weeks (mRAINBOW Regimen) in advanced gastroesophageal adenocarcinoma.
        Oncology. 2019; 96: 252-258
        • Conroy T.
        • Hammel P.
        • Hebbar M.
        • et al.
        • Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group
        FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer.
        N Engl J Med. 2018; 379: 2395-2406
        • Conroy T.
        • Desseigne F.
        • Ychou M.
        • et al.
        • Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup
        FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
        N Engl J Med. 2011; 364: 1817-1825
        • Von Hoff D.D.
        • Ervin T.
        • Arena F.P.
        • et al.
        Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
        N Engl J Med. 2013; 369: 1691-1703
        • Pusceddu S.
        • Ghidini M.
        • Torchio M.
        • et al.
        Comparative effectiveness of gemcitabine plus nab-paclitaxel and FOLFIRINOX in the first-line setting of metastatic pancreatic cancer: a systematic review and meta-analysis.
        Cancers (Basel). 2019; 11: 484
        • Kokkali S.
        • Drizou M.
        • Tripodaki E.
        • et al.
        Updated results of biweekly gemcitabine/nab-paclitaxel as first-line treatment for advanced pancreatic cancer.
        Ann Oncol. 2018; 29: v39
        • Rogers J.E.
        • Mizrahi J.D.
        • Shroff R.T.
        • et al.
        Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia.
        J Gastrointest Oncol. 2020; 11: 55-60
        • Tong H.
        • Fan Z.
        • Liu B.
        • Lu T.
        The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis.
        Sci Rep. 2018; 8: 8666
        • Pelzer U.
        • Schwaner I.
        • Stieler J.
        • et al.
        Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.
        Eur J Cancer. 2011; 47: 1676-1681
        • Wang-Gillam A.
        • Li C.P.
        • Bodoky G.
        • et al.
        • NAPOLI-1 Study Group
        Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
        Lancet. 2016; 387: 545-557
        • Gill S.
        • Ko Y.J.
        • Cripps C.
        • et al.
        PANCREOX: a randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy.
        J Clin Oncol. 2016; 34: 3914-3920
        • Primrose J.N.
        • Fox R.P.
        • Palmer D.H.
        • et al.
        • BILCAP study group
        Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
        Lancet Oncol. 2019; 20: 663-673
        • Valle J.
        • Wasan H.
        • Palmer D.H.
        • et al.
        • ABC-02 Trial Investigators
        Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
        N Engl J Med. 2010; 362: 1273-1281
        • Li J.
        • Merl M.
        • Lee M.X.
        • Kaley K.
        • Saif M.W.
        Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.
        Expert Opin Drug Saf. 2010; 9: 207-213
        • Kim S.T.
        • Kang J.H.
        • Lee J.
        • et al.
        Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
        Ann Oncol. 2019; 30: 788-795
        • Hyder O.
        • Marsh J.W.
        • Salem R.
        • et al.
        Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis.
        Ann Surg Oncol. 2013; 20: 3779-3786
        • Lamarca A.
        • Hubner R.A.
        • David Ryder W.
        • Valle J.W.
        Second-line chemotherapy in advanced biliary cancer: a systematic review.
        Ann Oncol. 2014; 25: 2328-2338
        • Lowery M.A.
        • Burris 3rd, H.A.
        • Janku F.
        • et al.
        Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
        Lancet Gastroenterol Hepatol. 2019; 4: 711-720
        • Mazzaferro V.
        • El-Rayes B.F.
        • Droz Dit Busset M.
        • et al.
        Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.
        Br J Cancer. 2019; 120: 165-171
        • Kudo M.
        • Finn R.S.
        • Qin S.
        • et al.
        Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
        Lancet. 2018; 391: 1163-1173
        • Abou-Alfa G.K.
        • Meyer T.
        • Cheng A.L.
        • et al.
        Cabozantinib in patients with advanced and progressing hepatocellular carcinoma.
        N Engl J Med. 2018; 379: 54-63
        • Bruix J.
        • Qin S.
        • Merle P.
        • et al.
        • RESORCE Investigators
        Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
        Lancet. 2017; 389: 56-66
        • Grothey A.
        • Sobrero A.F.
        • Shields A.F.
        • et al.
        Duration of adjuvant chemotherapy for stage III colon cancer.
        N Engl J Med. 2018; 378: 1177-1188
        • Cremolini C.
        • Antoniotti C.
        • Lonardi S.
        • et al.
        Activity and safety of cetuximab plus modified FOLFOXIRI followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a randomized phase 2 clinical trial.
        JAMA Oncol. 2018; 4: 529-536
        • Cremolini C.
        • Antoniotti C.
        • Rossini D.
        • et al.
        • GONO Foundation Investigators
        Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
        Lancet Oncol. 2020; 21: 497-507
        • Marmorino F.
        • Rossini D.
        • Lonardi S.
        • et al.
        Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies.
        Ann Oncol. 2019; 30: 1969-1977
        • Simkens L.H.
        • van Tinteren H.
        • May A.
        • et al.
        Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
        Lancet. 2015; 385: 1843-1852
        • Stein A.
        • Schwenke C.
        • Folprecht G.
        • Arnold D.
        Effect of application and intensity of bevacizumab-based maintenance after induction chemotherapy with bevacizumab for metastatic colorectal cancer: a meta-analysis.
        Clin Colorectal Cancer. 2016; 15: e29-e39
        • Aparicio T.
        • Ghiringhelli F.
        • Boige V.
        • et al.
        • PRODIGE 9 Investigators
        Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9).
        J Clin Oncol. 2018; 36: 674-681
        • Pietrantonio F.
        • Morano F.
        • Corallo S.
        • et al.
        Maintenance therapy with panitumumab alone vs panitumumab plus fluorouracil-leucovorin in patients with RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial.
        JAMA Oncol. 2019; 5: 1268-1275
        • Van Cutsem E.
        • Tabernero J.
        • Lakomy R.
        • et al.
        Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
        J Clin Oncol. 2012; 30: 3499-3506
        • Tabernero J.
        • Yoshino T.
        • Cohn A.L.
        • et al.
        • RAISE Study Investigators
        Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
        Lancet Oncol. 2015; 16: 499-508
        • Kopetz S.
        • Grothey A.
        • Yaeger R.
        • et al.
        Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer.
        N Engl J Med. 2019; 381: 1632-1643
        • Pietrantonio F.
        • Miceli R.
        • Rimassa L.
        • et al.
        Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the colon life nomogram.
        Ann Oncol. 2017; 28: 555-561
        • Bekaii-Saab T.S.
        • Ou F.S.
        • Ahn D.H.
        • et al.
        Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.
        Lancet Oncol. 2019; 20: 1070-1082
        • Bartelink H.
        • Roelofsen F.
        • Eschwege F.
        • et al.
        Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.
        J Clin Oncol. 1997; 15: 2040-2049
        • Oliveira S.C.
        • Moniz C.M.
        • Riechelmann R.
        • et al.
        Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with localized squamous cell carcinoma of the anal canal.
        J Gastrointest Cancer. 2016; 47: 75-81
        • Oehler-Janne C.
        • Huguet F.
        • Provencher S.
        • et al.
        HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy.
        J Clin Oncol. 2008; 26: 2550-2557
        • Ajani J.A.
        • Carrasco C.H.
        • Jackson D.E.
        • Wallace S.
        Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal.
        Am J Med. 1989; 87: 221-224
        • Rao S.
        • Scafani F.
        • Eng C.
        • et al.
        InterAACT: a multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial.
        Ann Oncol. 2018; 29: 715-716
        • Garcia-Carbonero R.
        • Sorbye H.
        • Baudin E.
        • et al.
        Vienna Consensus Conference participants. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas.
        Neuroendocrinology. 2016; 103: 186-194
        • Strosberg J.
        • El-Haddad G.
        • Wolin E.
        • et al.
        • NETTER-1 Trial Investigators
        Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors.
        N Engl J Med. 2017; 376: 125-135
        • Yao J.C.
        • Shah M.H.
        • Ito T.
        • et al.
        • RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group
        Everolimus for advanced pancreatic neuroendocrine tumors.
        N Engl J Med. 2011; 364: 514-523
        • Raymond E.
        • Dahan L.
        • Raoul J.L.
        • et al.
        Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
        N Engl J Med. 2011; 364: 501-513
        • Sorbye H.
        • Welin S.
        • Langer S.W.
        • et al.
        Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.
        Ann Oncol. 2013; 24: 152-160
        • Welin S.
        • Sorbye H.
        • Sebjornsen S.
        • et al.
        Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
        Cancer. 2011; 117: 4617-4622
        • Hadoux J.
        • Malka D.
        • Planchard D.
        • et al.
        Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma.
        Endocr Relat Cancer. 2015; 22: 289-298
        • Hentic O.
        • Hammel P.
        • Couvelard A.
        • et al.
        FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
        Endocr Relat Cancer. 2012; 19: 751-757
        • Le D.T.
        • Uram J.N.
        • Wang H.
        • et al.
        PD-1 blockade in tumors with mismatch-repair deficiency.
        N Engl J Med. 2015; 372: 2509-2520
        • Lala M.
        • Li M.
        • Sinha V.
        • et al.
        A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation.
        J Clin Oncol. 2018; 36: 3062
        • Falvella F.S.
        • Cheli S.
        • Martinetti A.
        • et al.
        DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
        Br J Clin Pharmacol. 2015; 80: 581-588
        • Diaz J.A.
        • Rai S.N.
        • Wu X.
        • Chao J.H.
        • Dias A.J.
        • Kloecker G.H.
        Phase II trial on extending the maintenance flushing interval of implanted ports.
        J Oncol Pract. 2017; 13: e22-e28
        • Solinas G.
        • Platini F.
        • Trivellato M.
        • Rigo C.
        • Alabiso O.
        • Galetto A.S.
        Port in oncology practice: 3-monthly locking with normal saline for catheter maintenance, a preliminary report.
        J Vasc Access. 2017; 18: 325-327
        • Guo T.
        • Fan Y.
        • Chen M.
        • et al.
        Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020 Mar 27;e201017.
        (Online ahead of print)
        • Ay C.
        • Pabinger I.
        • Cohen A.T.
        Cancer-associated venous thromboembolism: burden, mechanisms, and management.
        Thromb Haemost. 2017; 117: 219-230
        • Kraaijpoel N.
        • Di Nisio M.
        • Mulder F.I.
        • et al.
        Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE cancer study.
        Thromb Haemost. 2018; 118: 1439-1449